Back

A descriptive journey through the heart of transthyretin cardiac amyloidosis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease (2) Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mariana Rodrigues Simoes

Coimbra Hospital and University Center, Coimbra (Portugal)

8 More presentations in this session

Presentation thumbnail
Effects of tafamidis on pacemaker therapy
Doctor M. Figueiredo (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, mortality outcomes and survival predictors of transthyretin cardiac amyloidosis in an Asian registry
Doctor V. Putri (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Diagnostic value of the right ventricular wall thickness and free wall strain ratio in distinguishing hypertrophic cardiomyopathy and wild-type transthyretin cardiac amyloidosis
Doctor E. Mata (Creixomil, PT)
Abstract Slides Video
Presentation thumbnail
Red-flags for cardiac amyloidosis in real life of an internal medicine department
Doctor I. Fiteni Mera (Zaragoza, ES)
Abstract Slides Video
Presentation thumbnail
Associations between age and sex and cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Usefulness of a simple clinical score in identifying increased risk of transthyretin amyloid cardiomyopathy in older patients with unexplained hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan
thumbnail
Congress Presentation
Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources